

AXON NEUROSCIENCE SE

FINANCIAL STATEMENTS

For the year ended 31 December 2021

AXON NEUROSCIENCE SE

FINANCIAL STATEMENTS

For the year ended 31 December 2021

C O N T E N T S

	<u>Page</u>
Statement of financial position	1
Statement of profit or loss and other comprehensive income	2
Statement of changes in equity	3
Statement of cash flows	4

AXON NEUROSCIENCE SE

STATEMENT OF FINANCIAL POSITION

As at 31 December 2021

	2021	2020
	€	€
Assets		
Non-current assets		
Property, plant and equipment	57.215	72.954
Intangible assets	-	1.442.875
Investments in subsidiaries	4.828.000	4.828.000
Loans receivable	<u>1.347.003</u>	<u>1.290.628</u>
Total non-current assets	<u>6.232.218</u>	<u>7.634.457</u>
Current assets		
Inventories	1.662.554	1.476.459
Trade and other receivables	487.772	422.832
Other investments	500	500
Cash and cash equivalents	<u>102.864</u>	<u>991.571</u>
Total current assets	<u>2.253.690</u>	<u>2.891.362</u>
Total assets	<u>8.485.909</u>	<u>10.525.819</u>
Equity		
Share capital	27.512.000	27.512.000
Reserves	<u>(167.475.821)</u>	<u>(147.493.119)</u>
Total equity	<u>(139.963.821)</u>	<u>(119.981.119)</u>
Liabilities		
Current liabilities		
Short term loans	137.972.087	122.544.812
Trade and other payables	10.477.440	7.961.923
Tax liability	<u>203</u>	<u>203</u>
Total current liabilities	<u>148.449.730</u>	<u>130.506.938</u>
Total liabilities	<u>148.449.730</u>	<u>130.506.938</u>
Total equity and liabilities	<u>8.485.909</u>	<u>10.525.819</u>

On 26 August 2022

.....
 Daniel Legen
 Chairman of the Board of Directors

AXON NEUROSCIENCE SE

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOMEFor the year ended 31 December 2021

	2021	2020
	€	€
Other operating income	40.110	-
Administrative expenses	(8.994.119)	(14.007.876)
Other operating expenses	-	(1.897.397)
Operating loss	<u>(8.954.009)</u>	<u>(15.905.273)</u>
Finance income - total	56.375	57.438
Finance costs - total	<u>(11.085.068)</u>	<u>(10.305.281)</u>
Net finance expenses	<u>(11.028.693)</u>	<u>(10.247.843)</u>
Loss before tax	(19.982.702)	(26.153.116)
Tax	-	-
Loss for the year	<u>(19.982.702)</u>	<u>(26.153.116)</u>
Other comprehensive income	-	-
Total comprehensive expense for the year	<u>(19.982.702)</u>	<u>(26.153.116)</u>

AXON NEUROSCIENCE SE

STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2021

	Share capital €	Reserves €	Retained earnings €	Total €
Balance at 1 January 2020	27.512.000	24.959.794	(146.299.797)	(93.828.003)
Comprehensive income				
Loss for the year	-	-	(26.153.116)	(26.153.116)
Balance at 31 December 2020	<u>27.512.000</u>	<u>24.959.794</u>	<u>(172.452.913)</u>	<u>(119.981.119)</u>
Balance at 1 January 2021	27.512.000	24.959.794	(172.452.913)	(119.981.119)
Comprehensive income				
Loss for the year	-	-	(19.982.702)	(19.982.702)
Balance at 31 December 2021	<u>27.512.000</u>	<u>24.959.794</u>	<u>(192.435.615)</u>	<u>(139.963.821)</u>

AXON NEUROSCIENCE SE

STATEMENT OF CASH FLOWSFor the year ended 31 December 2021

	2021	2020
	€	€
Cash flows from operating activities		
Loss for the year	(19.982.702)	(26.153.116)
Adjustments for:		
Depreciation of property, plant and equipment	15.738	69.495
Unrealised exchange loss	621	-
Amortisation of trademarks and licences	1.442.874	1.442.875
Impairment charge - property, plant and equipment	-	1.897.397
Interest income	(56.375)	(56.529)
Interest expense	<u>11.077.275</u>	<u>10.294.076</u>
Cash used in operations before working capital changes	<u>(7.502.569)</u>	<u>(12.505.802)</u>
(Increase)/decrease in inventories	(186.095)	1.425.976
Increase in trade and other receivables	(64.940)	(24.147)
Increase/(decrease) in trade and other payables	<u>2.515.518</u>	<u>(965.750)</u>
Cash used in operations	<u>(5.238.086)</u>	<u>(12.069.723)</u>
Cash flows from investing activities		
Payment for acquisition of investments in subsidiaries	-	(176.000)
Net cash used in investing activities	<u>-</u>	<u>(176.000)</u>
Cash flows from financing activities		
Repayment of borrowings	-	(7.882.857)
Proceeds from borrowings	15.427.275	18.310.000
Unrealised exchange (loss)	(621)	-
Interest paid	<u>(11.077.275)</u>	<u>(57.185)</u>
Net cash generated from financing activities	<u>4.349.379</u>	<u>10.369.958</u>
Net decrease in cash and cash equivalents	<u>(888.707)</u>	<u>(1.875.765)</u>
Cash and cash equivalents at beginning of the year	<u>991.571</u>	<u>2.867.336</u>
Cash and cash equivalents at end of the year	<u>102.864</u>	<u>991.571</u>